{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Surmodics, Inc.
Surmodics, Inc. Hits New 52-Week High of $41.72
Surmodics, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 41.72 on November 14, 2025, significantly up from its low of USD 25.87. With a market cap of USD 471 million, the company faces challenges, including a negative return on equity and no dividend yield.
Surmodics, Inc. Hits New 52-Week High at USD 41.65
Surmodics, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 41.65 on November 12, 2025. Despite this milestone, the company has faced a decline in stock price over the past year and currently reports negative financial metrics, including a loss-making status.
Surmodics, Inc. Hits New 52-Week High at $41.20
Surmodics, Inc. has achieved a new 52-week high of USD 41.20, significantly up from its low of USD 25.87. Despite this milestone, the company has seen a 1-year performance decline of 2.2%. With a market cap of USD 471 million, Surmodics faces challenges in profitability.
Surmodics, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead
Surmodics, Inc. has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The company is facing a challenging environment, with a one-year performance decline of nearly 28%, contrasting sharply with the S&P 500's gains. Technical indicators suggest a bearish outlook for the stock.
Is Surmodics, Inc. technically bullish or bearish?
As of August 29, 2025, Surmodics, Inc. shows a mildly bullish trend driven by weekly MACD and Bollinger Bands, despite underperforming the S&P 500 with a year-to-date return of -18.64%.
Is Surmodics, Inc. overvalued or undervalued?
As of July 31, 2024, Surmodics, Inc. is considered overvalued and risky due to a high Price to Book Value of 3.81, an EV to EBITDA ratio of 91.89, negative returns on equity and capital, and poor stock performance, with a year-to-date return of -18.64% compared to the S&P 500's 12.22%.
Surmodics Reports Mixed Financial Results, Highlighting Profit Growth and Sales Challenges in June 2025
Surmodics, Inc. recently announced its financial results for the quarter ending June 2025, showcasing notable improvements in net profit and operating profit, both reaching their highest levels in five periods. However, the debtors turnover ratio declined, indicating challenges in managing receivables. Overall, the results reflect mixed financial performance.
Is Surmodics, Inc. overvalued or undervalued?
As of July 31, 2024, Surmodics, Inc. is considered risky and overvalued due to high Price to Book and EV to EBITDA ratios, negative returns on capital and equity, and poor performance compared to the S&P 500.
Is Surmodics, Inc. technically bullish or bearish?
As of May 19, 2025, Surmodics, Inc. shows a mildly bearish technical trend with mixed signals across various indicators, suggesting a cautious outlook.
Who are in the management team of Surmodics, Inc.?
As of March 2022, the management team of Surmodics, Inc. includes Non-Executive Independent Chairman Ms. Susan Knight, President and CEO Mr. Gary Maharaj, and Independent Directors Mr. Jose Bedoya, Dr. David Dantzker, Ms. Lisa Heine, and Mr. Ronald Kalich. This team combines executive leadership with independent oversight for the company's governance and strategy.
What does Surmodics, Inc. do?
Surmodics, Inc. is a micro-cap company that develops medical device and in vitro diagnostic technologies, reporting net sales of $28 million and a net loss of $5 million as of March 2025. The company has a market cap of $415.39 million and does not currently pay dividends.
How big is Surmodics, Inc.?
As of Jun 18, Surmodics, Inc. has a market capitalization of 415.39 million, with net sales of 121.58 million and a net profit of -19.86 million over the latest four quarters. As of September 24, the company reported shareholder's funds of 118.90 million and total assets of 178.56 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
